Ọgbẹni Olawale Dawodu~
The World Health Organization (WHO) has approved the first-ever malaria treatment specifically designed for babies, marking a major breakthrough in the fight against the disease that disproportionately affects young children.
Malaria remains one of the leading causes of death globally, with children under the age of five accounting for more than two-thirds of all fatalities. Health experts say the newly approved drug targets this highly vulnerable group, offering renewed hope for reducing mortality rates.
The WHO said the treatment is tailored to meet the unique medical needs of infants, a category that has long lacked appropriate malaria therapies. The development is expected to improve survival chances and strengthen ongoing efforts to curb the disease, particularly in high-burden regions such as sub-Saharan Africa.
Public health stakeholders have welcomed the approval, describing it as a critical step toward closing treatment gaps and protecting millions of at-risk children worldwide.
